<DOC>
	<DOCNO>NCT01434602</DOCNO>
	<brief_summary>The goal Phase 1 clinical research study find high tolerable dose best schedule combination everolimus sorafenib give patient malignant glioma . The goal Phase 2 study learn combination everolimus sorafenib help control malignant glioma . The safety combination also study phase .</brief_summary>
	<brief_title>Phase I-II Everolimus Sorafenib Recurrent High-Grade Gliomas</brief_title>
	<detailed_description>Background - Although malignant glioma display genetic heterogeneity , several key proliferation survival signal pathway identify . - Recent work focus target tumor specific pathways hop improve treatment efficacy minimize treatment toxicity . Because molecularly target agent mostly ineffective use alone , combination therapy inhibit multiple pathway appeal strategy . - Sorafenib oral multi-kinase inhibitor effect tumor proliferation tumor angiogenesis . Although GBMs lack RAF mutation , target RAF/MEK/ERK pathway may beneficial pathway may activate genetic alteration upstream RAF . - The mammalian target rapamycin ( mTOR ) protein downstream component PI3K/Akt pathway . Everolimus ( everolimus ; Novartis ) novel oral derivative rapamycin . - Combining everolimus sorafenib allow target PI3K pathway RAF-MAPK pathway addition target VEGF PDGF , active target malignant glioma . Objectives Phase 1 -To determine maximum tolerate dose safety everolimus combination sorafenib patient recurrent malignant glioma . Phase 2 - 6 month progression free survival rate glioblastoma patient prior bevacizumab exposure treat everolimus sorafenib maximum tolerate dose determined phase I study . - 3 month progression free survival rate glioblastoma patient prior bevacizumab exposure treat everolimus sorafenib maximum tolerate dose determined phase I study . - 6 month progression free survival rate AG patient prior bevacizumab exposure treat everolimus sorafenib maximum tolerate dose determined phase I study . Eligibility - Patients histologically proven recurrent intracranial malignant glioma eligible phase I/II component protocol . - Patients must &gt; 18 year old Karnofsky performance status great equal 60 - No 2 prior chemotherapy 1 relapse . Prior bevacizumab therapy allow . Design - This phase 1 /2 study everolimus sorafenib patient recurrent highgrade glioma . - Phase 1 : Patients treat daily everolimus ( day 1-28 ) combination sorafenib . - Phase 2 : Patients treat combination sorafenib everolimus . Sorafenib take daily 7 day , 7 day . Everolimus take daily . - There define set maximum number cycle patient may . Patients may continue protocol therapy criterion Off Treatment meet . - There accrual approximately 3-6 eligible patient per cohort Phase I component study . Patients remove time toxicity evaluable . Phase I patient remove study treatment within 28 day reason toxicity may replace . - There total accrual approximately 82 eligible patient Phase II study ( 34 recurrent GBM prior exposure bevacizumab , 16 recurrent Anaplastic Glioma prior exposure bevacizumab , 32 glioblastoma prior exposure bevacizumab ) .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>INCLUSION CRITERIA : General Inclusion Criteria 1 . Patients histologically proven recurrent intracranial malignant glioma eligible phase I/II component protocol . Malignant glioma include glioblastoma multiforme ( GBM ) , Gliosarcoma ( GS ) , anaplastic astrocytoma ( AA ) , anaplastic oligodendroglioma ( AO ) , anaplastic mixed oligoastrocytoma ( AMO ) , malignant astrocytoma NOS ( otherwise specify ) . Patients eligible original histology lowgrade glioma subsequent histological diagnosis malignant glioma make . 2 . All patient must sign informed consent indicate aware investigational nature study . Patients must sign authorization release protect health information sit except NIH . 3 . Patients must great equal 18 year old . 4 . Patients must Karnofsky performance status great equal 60 . 5 . No 2 prior chemotherapy 1 relapse . Prior bevacizumab therapy allow . Patients must recover toxic effect prior therapy : &gt; 3 week biologic therapy noncytotoxic therapy , &gt; 4 week cytotoxic therapy , &gt; 6 week nitrosoureas . Any question relate definition non cytotoxic agent direct Academic PI . NOTE : 13 cisretinoic acid ( Accutane ) biologic therapy washout period 14 day . 6 . Patients must adequate bone marrow function ( WBC great equal 3,000/microliters , ANC great equal 1,500/mm3 , platelet count great equal 100,000/mm3 , hemoglobin great equal 10 gm/dl ) , adequate liver function ( SGOT bilirubin &lt; 2 time ULN ) , adequate renal function ( creatinine &lt; 1.7mg/dL creatinine clearance great equal 60 cc/min ) start therapy . These test must perform within 14 day prior registration . Eligibility level hemoglobin may reach transfusion . 7 . Patients must show unequivocal radiographic evidence tumor progression MRI CT scan . A scan performed within 14 day prior registration steroid dose stable decrease least 5 day . If steroid dose increase date image registration new baseline MRI/CT require . The type scan , i.e. , MRI CT must use throughout period protocol treatment tumor measurement . Measurable disease NOT require . Note : MRI preferable imaging method ; CT scan may use case MRI obtain . 8 . Patients undergone recent resection recurrent progressive tumor eligible long follow condition apply : They recover effect surgery &gt; 3 week surgery . Residual disease follow resection recurrent malignant glioma mandate eligibility study . To best assess extent residual disease postoperatively , CT/ MRI do later 96 hour immediate postoperative period least 4 week postoperatively , within 14 day prior registration . If 96hour scan 14 day registration , scan need repeat . If steroid dose increase date imaging registration , new baseline MRI/CT require stable steroid dosage least 5 day . 9 . Patients must fail prior radiation therapy must interval great equal 12 week completion radiation therapy registration ; except patient underwent surgery within 12 week pathology consistent recurrent tumor . 10 . Patients prior therapy include interstitial brachytherapy stereotactic radiosurgery must confirmation true progressive disease rather radiation necrosis base upon either PET Thallium scanning , MR spectroscopy surgical/pathological documentation disease . 11 . Women childbearing potential must negative BHCG pregnancy test document within 14 day prior take first dose study medication . 12 . Patients receive anticoagulation treatment agent warfarin heparin may allow participate . For patient warfarin , INR measure prior initiation sorafenib monitor least weekly , define local standard care , INR stable . Phase I The follow modification general eligibility criterion apply Phase I patient . Patients may treatment number prior relapse . Relapse define progression follow initial therapy ( i.e . surgery radiation+/ chemo use initial therapy ) . Phase II Phase II patient must meet following Eligibility Criteria addition General Criteria describe . Patients may treatment 1 prior relapse ( i.e . fail 2 line treatmentinitial therapy therapy first relapse ) 2nd relapse , treatment per BTTC0901 option . Relapse define progression follow initial therapy ( i.e . radiation+/ chemo use initial therapy ) . The intent therefore patient 2 prior therapy ( initial treatment 1 relapse ) . If patient surgical resection relapse disease anticancer therapy institute 12 week , patient undergoes another surgical resection , consider 1 relapse . For patient prior therapy lowgrade glioma , surgical diagnosis highgrade glioma consider first relapse . Patients must receive prior therapy sorafenib , everolimus , relate drug tyrosine kinase inhibitor , VEGF inhibitor ( except bevacizumab ) , mTOR inhibitor . EXCLUSION CRITERIA : General Exclusion Criteria 1 . Patients must significant medical illness investigator opinion adequately control appropriate therapy would compromise patient ability tolerate therapy 2 . Patients history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) , unless complete remission therapy disease minimum 3 year ineligible . 3 . Patients must active infection serious intercurrent medical illness . 4 . Patients must disease obscure toxicity dangerously alter drug metabolism . 5 . Patients must enzyme induce anticonvulsant . If patient previously EIAEDs discontinue , patient must agent least 2 week prior first study drug administration . For patient need start AED AED need change , strongly recommend effort make use nonEIAED . 6 . Patients severe and/or uncontrolled medical condition condition could affect participation study : Symptomatic congestive heart failure New York heart Association Class III IV unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction within 6 month start study drug clinically significant cardiac disease severely impaired lung function define spirometry DLCO 50 % normal predict value and/or 02 saturation 88 % less rest room air uncontrolled diabetes define fast serum glucose &gt; 1.5 x ULN , active ( acute chronic ) uncontrolled severe infection , liver disease cirrhosis , chronic active hepatitis chronic persistent hepatitis . 7 . Cardiac ventricular arrhythmia require antiarrhythmic therapy . 8 . Uncontrolled hypertension define systolic blood pressure &gt; 140 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management . 9 . Known human immunodeficiency virus ( HIV ) infection chronic acute Hepatitis B C. Note : Patients history HBV HCV infection eligible , however , must receive prophylactic antiviral therapy 12 week prior receive study drug . 10 . Thrombolic embolic event ( except DVT pulmonary embolus ) Cerebrovascular accident include transient ischemic attack within past 6 month . 11 . Pulmonary hemorrhage/bleeding event great equal CTCAE Grade 2 within 4 week first dose study drug . 12 . Any hemorrhage/bleeding event great equal CTCAE Grade 3 within 4 week first dose study drug . 13 . Serious nonhealing wound , nonhealing ulcer , bone fracture . 14 . Evidence history bleed diathesis coagulopathy 15 . Major surgery , open biopsy significant traumatic injury within 4 week first study drug . 16 . Use St. John Wort , orrifampin ( rifampicin ) , strong CYP34A inducer . Dexamethasone okay long dose 16 mg /day less . Note : Patients reference medication may consider eligible washout period 14 day . Contact coordinate center discus patient aforementioned agent patient registration . 17 . Known suspected allergy sorafenib , everolimus , agent give course trial . 18 . Any condition impairs patient ability swallow whole pill . 19 . Any malabsorption problem . 20 . Other malignancy within past 3 year except adequately treat carcinoma cervix basal squamous cell carcinoma skin . 21 . Female patient pregnant breast feeding , adult reproductive potential use effective birth control method . Barrier contraceptives must use throughout trial sex . Hormonal contraceptives acceptable sole method contraception . ( Women childbearing potential must negative urine serum pregnancy test within 14 day prior administration everolimus sorafenib ) . 22 . Patients receive prior treatment mTOR inhibitor ( sirolimus , temsirolimus , everolimus ) . 23 . Patients know hypersensitivity everolimus rapamycins ( sirolimus , temsirolimus ) excipients . 24 . History noncompliance medical regimen . 25 . Patients unwilling unable comply protocol . 26 . Patients total daily dose dexamethasone great 16 mg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 1, 2016</verification_date>
	<keyword>Chemotherapy</keyword>
	<keyword>Brain Tumor</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Anaplastic Glioma</keyword>
</DOC>